Table 2.
Trials | Phase | Dose (mg) | No. of pts | Treatment | Best response |
---|---|---|---|---|---|
GAUGUIN | I | 400–1200 | 13 | O | ORR 62% |
GAUGUIN | II | 1000 | 20 | O | ORR 30% |
GALTION | Ib | 1000 | 20 | O+B | ORR 90% |
GALTION | 21 | O+FC | ORR 62% | ||
GAGE | II | 1000 | 41 | O | ORR 49% |
GAGE | 2000 | 39 | O | ORR 66% | |
CLL11 | III (stage 1) | 1000 | 238 | O+C | ORR 31% |
CLL11 | 233 | R+C | ORR 79% | ||
CLL11 | (stage 2) | 330 | R+C | ORR 65% | |
CLL11 | 333 | O+C | ORR 78.4% |
Abbreviations: O, obinutuzumab; B, bendamustine; FC, fludarabine/cyclophosphamide; R, rituximab; C, chlorambucil; ORR, overall response rate.